Status:
COMPLETED
Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to assess the impact of patient cost sharing on treatment discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)
Eligibility Criteria
Inclusion
- Patients diagnosed with Rheumatoid Arthritis (RA) who newly initiated a biologic DMARD (bDMARD) during a study timeframe of 1/01/06 to 3/31/09.
- 18 to 64 years of age at index date
- Diagnosis of RA during the study period (ICD-9CM 714.xx)
- Evidence of at least one biologic DMARD of interest during the study timeframe
- Continuous enrollment during the study timeframe
- Both medical and pharmacy benefits
- No evidence of a claim for a bDMARD in the 6-month pre-period
Exclusion
- Patients are excluded if they have a diagnosis of psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis at any time during the study timeframe; have a claim for Rituxan, IV etanercept, or IV adalimumab; or have Medicare or Medicaid during the study timeframe
Key Trial Info
Start Date :
November 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
3940 Patients enrolled
Trial Details
Trial ID
NCT01137851
Start Date
November 1 2009
End Date
September 1 2010
Last Update
October 1 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.